Aspen secures licensing agreement to enter GLP-1 market

Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Tagged Aspen Pharmacare, diabetes treatment, GLP-1 agonist market, GLP-1 drugs, licensing agreement, manufacturing facilities, obesity treatment, pharmaceutical growth, Stephen Saad, sterile injectables